30.06.2010 • News • Sanofi • TargeGen • Mergers & Acquisitions (M&A)

Sanofi Buys TargeGen to Boost Cancer Treatments

Sanofi-Aventis is to buy U.S. biotech TargeGen, which is developing treatments against blood diseases, for as much as $560 million as part of the French drugmaker's drive to boost its cancer treatments.

At the closing of the takeover, expected in the third quarter, Sanofi will pay $75 million and the rest will follow depending on the development of TargeGen's main product TG 101348 which aims to treat a chronic bone marrow disorder.

Privately held TargeGen, based in San Diego, Calf., develops small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other haematological malignancies and blood disorders. Sanofi has created a separate oncology unit to expand its portfolio of cancer treatments. Oral treatment TG 101348 has completed a clinical Phase I/II trial in patients with myelofibrosis, which disrupts the body's regular production of blood cells. Additional clinical studies are planned to start in the second half of 2010.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Top-Feature